ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026 Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility Fourth quarter and full year 2025 net product revenue of...

Read More